Sidley is the only Hong Kong counsel which advised five projects since the introduction of the new listing regime. We have assisted Shanghai Henlius Biotech, Inc., Viva Biotech Holdings, CanSino Biologics Inc. and Ascletis Pharma Inc. on their successful listings as well as Alphamab Oncology’s listing application submission. As of the third quarter of 2019, Sidley ranks No. 1 in the Hong Kong IPO league table by deal numbers.
Sidley has been ranked as a No. 1 issuers' legal adviser on U.S. capital markets transactions for the past 10 years. Recently, we represented Aprea Therapeutics, Inc. (NASDAQ GS: APRE) in its US$98 million initial public offering.
We have a market-leading IPO team consisting of experienced corporate lawyers and life science industry veterans. We are able to help you in navigating the complex uncertainties and challenges with value-added services.
*Source: RyanBen Capital, “Hong Kong: The World’s Second Largest Funding Hub for Biotech in 2019”
As of September 30, 2019, 16 biotech companies have been listed on the main board of SEHK and 14 biotech or medical companies have submitted their listing applications or have had their IPOs pending approvals since the launch of Hong Kong’s new listing regime in April, 2018. Among the 30 biotech IPOs, Sidley is the only Hong Kong counsel which advised up to five projects.